PARP1 and cancer: Therefore, the recent surge in the use of PARP inhibitors in combination with alkylating agents might represent a powerful tool for obtaining better therapeutic efficacy in cancer treatment, while avoiding the collateral effects of alkylating agents in healthy tissues of the subpopulations mentioned above.